MIJ-821 is a Small Molecule owned by Novartis, and is involved in 5 clinical trials, of which 2 were completed, 1 is ongoing, and 2 are planned.

MIJ-821 acts by negatively modulating the abnormal function of NMDA receptors 2B in brain. The NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. NR2B negative allosteric modulator acts by binding to the NMDA receptor and inhibiting the activity of NMDA receptors, thereby inhibiting the abnormal neurotransmission that checks the progression of depression.

The revenue for MIJ-821 is expected to reach a total of $60m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the MIJ-821 NPV Report.

MIJ-821 was originated by Cadent Therapeutics and is currently owned by Novartis.

MIJ-821 Overview

MIJ-821 is under development for the treatment of treatment resistant depression, major depressive disorder (MDD). The drug candidate is administered as intravenous and subcutaneous infusion. MIJ-821 acts by targeting NR2B. It is developed based on subtype-selective NMDA receptor (SNRMs) technology. It is a new molecular entity (NME).

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.

Quick View – MIJ-821

Report Segments
  • Innovator
Drug Name
  • MIJ-821
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.